

A group of children in a grassy field. In the foreground, a boy on the left wears a red and white striped shirt and grey shorts, holding a stick over his shoulders. Next to him, a girl in a red shirt and patterned skirt looks serious. To her right, a girl in an orange shirt and dark blue skirt smiles. Further right, a boy in a white t-shirt and dark shorts smiles. In the background, other children are scattered across the field, some running and some standing. The scene is outdoors with trees and a building in the distance.

ACCELERATING INNOVATION

2013 ANNUAL REPORT



PATH accelerates innovation
that transforms lives.
Here's what PATH and our
partners catalyzed in 2013.

From PATH's president and board chair

As the leading innovator in global health, PATH is driven by an unshakeable commitment to health equity and a bold belief in the power of innovation to improve health and save lives, especially among women and children. We bring together the right tools and people at the right time and place, accelerating innovations that create better health and new opportunities for all.

In 2013, PATH and our partners touched the lives of more than 219 million people with new vaccines and drug treatments, breakthrough health tools, and powerful strategies to change the course of disease. The milestones featured here reflect the very best of PATH—and our ingenuity, insight, and relentless determination to dismantle every barrier to progress.

We know we can do even more. This year, we launched a new One PATH strategy that harnesses PATH's unique capabilities and broad network of partners across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations. This five-year strategy will sharpen our focus on tackling the top health threats to women and children, significantly contributing to the Millennium Development Goals and other



global targets. Together with our partners, we will accelerate our work on the nearly 200 tools and technologies in our development pipeline to bring health within reach for everyone.

Our commitment to collaboration and to the effective use of the resources entrusted to us remains central to our work. With your support, we are fueling transformative change in the lives of the world's most vulnerable women and children. Thank you for your continued partnership.

Steve Davis
President and CEO

George Gotsadze, MD, PhD
Chair, Board of Directors



Trailblazing strategies to develop and deliver vaccines



VACCINES



DRUGS



DIAGNOSTICS



DEVICES



SYSTEM AND
SERVICE
INNOVATIONS

VACCINES

PATH accelerates the development and delivery of lifesaving vaccines. Our portfolio includes vaccines for diarrheal disease, influenza, Japanese encephalitis, malaria, meningitis, pneumococcal disease, polio, and more, as well as innovative delivery strategies to ensure vaccines reach the most vulnerable.

Landmark protection for Asia's children

with a Japanese encephalitis vaccine now approved by WHO




VACCINES

PATH led a ten-year effort that turned a little-known vaccine from China into an internationally approved tool to fight Japanese encephalitis, a disease that kills three in ten people infected.

We identified an effective vaccine in China that was virtually unknown outside the country. We helped the manufacturer meet regulatory standards, secured an affordable public-sector price, and prepared countries to introduce it. The World Health Organization (WHO) granted the vaccine its stamp of approval in October 2013. Now we are working with partners to continue rolling out the vaccine across Asia, starting with campaigns in Laos and Cambodia that are expected to reach more than 500,000 children by 2015.

Countries across Asia have rolled out the Japanese encephalitis vaccine with PATH's support.



IMPACT

200 million+ people vaccinated in 11 countries.

KEY PARTNERS: Chengdu Institute of Biological Products; China National Biotech Group Co., Ltd.; GAVI Alliance; WHO; ministries of health across Asia.

KEY FUNDERS: Bill & Melinda Gates Foundation; individual contributors.

A historic drop in meningitis cases

and a breakthrough that could help vaccines reach the most remote areas




VACCINES

New evidence confirms the groundbreaking impact of the MenAfriVac® vaccine, developed by PATH, WHO, and Serum Institute of India Ltd. to protect against deadly meningitis A. According to a study in the *Lancet*, the incidence of meningitis of any kind dropped by 94% following a mass immunization campaign in Chad.

A second study found that the vaccine can be kept out of the traditional 2°C to 8°C temperature range for up to four days without losing potency. It's a breakthrough that could extend the reach of other vaccines to remote areas where keeping vaccines cold is difficult—an approach that researchers estimate could cut storage and transportation costs in half.

MenAfriVac is a registered trademark of Serum Institute of India Ltd.

Number of people receiving the MenAfriVac vaccine in 12 African countries (in millions), 2010–2013.



IMPACT

No cases of meningitis A among the 153 million+ Africans vaccinated since 2010.

KEY PARTNERS: Serum Institute of India Ltd.; WHO; ministries of health in Africa; three dozen global collaborators.

KEY FUNDERS: Bill & Melinda Gates Foundation; Michael & Susan Dell Foundation; National Philanthropic Trust; Shefa Fund hosted by the Swiss Philanthropy Foundation; US Agency for International Development (USAID); US Centers for Disease Control and Prevention (CDC); GAVI Alliance; individual contributors.



*MenAfriVac is the
first vaccine designed
specifically for Africa.*

An affordable new vaccine against diarrhea and a cross-sector partnership model for developing health technologies



VACCINES

A new vaccine awaiting licensure in India promises to transform the fight against rotavirus, the most lethal cause of diarrhea. ROTAVAC® protects children at a fraction of the price of currently available vaccines. PATH provided technical support on clinical trials and manufacturing issues as part of a unique social innovation partnership, with public- and private-sector partners sharing the risks and costs of vaccine development. This new model could spur the development of other vaccines to meet the needs of low-income countries. We are also working with partners to submit ROTAVAC for WHO prequalification once licensure is granted, a key step in reaching more children.

PATH also helped introduce currently available rotavirus vaccines to seven new countries in 2013 through advocacy and communications support.

ROTAVAC is a registered trademark of Bharat Biotech International Ltd.



PATH/Cabe Bienzycki

At just \$1 per dose, ROTAVAC could save the lives of thousands of children in low-income countries.

IMPACT

ROTAVAC reduces severe rotavirus diarrhea by 56% in the first year of life, according to a study in the *Lancet*.

KEY PARTNERS: Bharat Biotech International Ltd.; CDC; Government of India's Department of Biotechnology; Johns Hopkins University; National Institutes of Health; ROTA Council; Society for Applied Studies; Stanford University School of Medicine; UNICEF; WHO.

KEY FUNDERS: Bill & Melinda Gates Foundation; GAVI Alliance; Research Council of Norway; UK Department for International Development.

A promising malaria vaccine nears the finish line

offering new hope in the fight against a top killer



VACCINES

What many once thought impossible—developing a vaccine for human use against a parasite—is now on the cusp of reality. PATH is collaborating with GlaxoSmithKline and others in the final phase of clinical trials that could lead to the licensure of a new vaccine shown to help protect young children against the deadliest malaria parasite.

A phase 3 trial with more than 15,000 African children found that the vaccine candidate, RTS,S, continued to protect infants and toddlers from clinical malaria up to 18 months after vaccination. Final trial results will inform a WHO policy recommendation as early as 2015, indicating whether African countries should consider including RTS,S in their immunization programs.



These children in Tanzania are among more than 15,000 African children participating in a phase 3 clinical trial of RTS,S, the most clinically advanced malaria vaccine candidate.

IMPACT

Cases of clinical malaria dropped by 46% among toddlers and 27% among infants receiving the RTS,S vaccine candidate during 18 months of follow-up.

KEY PARTNERS: GlaxoSmithKline; scientists in Africa, Europe, and the United States.

KEY FUNDERS: Bill & Melinda Gates Foundation; individual contributors.

Groundbreaking approaches to drug development



VACCINES



DRUGS



DIAGNOSTICS



DEVICES



SYSTEM AND
SERVICE
INNOVATIONS

DRUGS

PATH develops and introduces affordable drugs for diseases that disproportionately affect people in low-income countries, including drugs to treat or prevent diarrhea, HIV, malaria, and newborn infections.

A new source of malaria treatment

through a semisynthetic version of artemisinin now prequalified by WHO




DRUGS

Millions more people will benefit from the gold-standard malaria treatment, thanks to a global partnership convened by PATH that developed a semisynthetic form of artemisinin, the key ingredient in artemisinin-based combination therapies (ACTs). The first nonplant-derived source of artemisinin complements the world's botanical supply, with the goal of stabilizing prices and ensuring a dependable flow of artemisinin to the market.

The launch of industrial-scale production and WHO prequalification in 2013 capped a nine-year effort to turn this ambitious idea into lifesaving reality. Up to 60 metric tons can be produced each year—enough to meet one-third of the total global need.

Producing semisynthetic artemisinin takes just three months, ensuring a more reliable supply to help meet demand for ACTs.



IMPACT

Up to 125 million malaria treatments per year.

KEY PARTNERS: Amyris, Inc.; Sanofi; University of California, Berkeley.

KEY FUNDER: Bill & Melinda Gates Foundation.

A powerful weapon against newborn infections

with a new version of an antiseptic endorsed by WHO to protect babies



DRUGS

Cutting the umbilical cord at birth marks a baby's first step toward independence. But in developing countries, that simple act too often creates an entry point for deadly infections.

PATH leads an international effort that began in 2007 to adapt a proven antiseptic called chlorhexidine into a new formulation for use on the cord after it is cut. In 2013, WHO endorsed the product, and implementation is under way in 16 countries. Now we are scaling up this lifesaving innovation by supporting country adoption and regional production in Africa to increase availability.

Sixteen countries are now implementing chlorhexidine programs to reach newborns with this lifesaving product.



IMPACT

An estimated 300,000 babies could be saved annually at a cost of less than 50 cents a dose.

KEY PARTNERS: Members of the Chlorhexidine Working Group.

KEY FUNDERS: United Nations Commission on Life-saving Commodities for Women and Children through UNICEF; USAID.



Infection causes about 13% of the 3 million newborn deaths each year. Lack of hygiene and antiseptics increases the risk of infections.

Breakthroughs in detecting disease



VACCINES



DRUGS



DIAGNOSTICS



DEVICES



SYSTEM AND
SERVICE
INNOVATIONS

DIAGNOSTICS

PATH develops and introduces fast, accurate diagnostic technologies to detect and track cervical cancer, diabetes, HIV, malaria, neglected tropical diseases, tuberculosis, and more.

A game-changing test for river blindness

thanks to a new diagnostic tool that can detect exposure to the disease in minutes




DIAGNOSTICS

PATH developed a new diagnostic tool that promises to accelerate efforts to eliminate river blindness, or onchocerciasis, a leading cause of preventable blindness in Africa. It's the only antibody test for the detection of river blindness tailored for use in the rural and remote settings where people are most affected by the disease.

This parasitic infection is transmitted through the bite of the blackfly, causing skin disfigurement as well as blindness and driving communities away from productive farm land for fear of infection.

The affordable, easy-to-use test will support ongoing efforts toward disease control and elimination and help prevent reemergence in endemic areas. The test requires only a drop of blood from a finger prick, with results available within 20 minutes. In 2013, we transferred the technology to a South Korean manufacturer and are working together to bring the test to market by the end of this year.



PATH/Dunia Faulx

A new test for river blindness uses a drop of blood and is fast, accurate, and easy to use.

IMPACT

A new tool to fight a disease threatening 180 million+ people worldwide.

KEY PARTNERS: African Program for Onchocerciasis Control; Bio-Rad/AbD Serotec; Erasmus University Rotterdam; National Institutes of Health; Standard Diagnostics Inc.; The Task Force for Global Health; Togo Ministry of Health; University of Tübingen.

KEY FUNDER: Bill & Melinda Gates Foundation.



Tools that put women in charge of their health



VACCINES



DRUGS



DIAGNOSTICS



DEVICES



SYSTEM AND
SERVICE
INNOVATIONS



DEVICES

PATH works with the people we serve to develop, adapt, and introduce health devices that improve maternal, reproductive, and newborn health; nutrition; and water and sanitation.

Family planning, reimagined


with two new barrier contraceptives that expand protection options for women



DEVICES

The **SILCS diaphragm**—a one-size-fits-most contraceptive device—is the first new cervical barrier method to reach the market in more than a decade. It went on sale in six European countries in 2013 and is now being reviewed for US regulatory approval. PATH led a public-private partnership that developed

The SILCS diaphragm



this reusable, nonhormonal device, informed by input from women and their partners. Next, we'll assess where and how to introduce the device in low-resource settings, with market assessments under way in India, South Africa, and Uganda.

The **Woman's Condom** (pictured on the preceding page) was designed by PATH and our partners with input from users to be a next-generation female condom. It was approved for sale in South Africa in 2013. It protects women from both pregnancy and sexually transmitted infections, including HIV. A WHO review now in process could lead to bulk public-sector purchases by United Nations agencies and others.

We are building demand for female condoms overall through campaigns that include an international film contest, with winning films screened in more than ten countries last year.

IMPACT

New options for 222 million women worldwide who want to avoid pregnancy but aren't using modern contraception.

KEY PARTNERS: SILCS diaphragm: CONRAD; Kessel Marketing & Vertriebs GmbH. Woman's Condom: CONRAD; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Shanghai Dahua Medical Apparatus Co., Ltd.

KEY FUNDERS: SILCS diaphragm: Bill & Melinda Gates Foundation; USAID; individual contributors. Woman's Condom: Bill & Melinda Gates Foundation; The Lemelson Foundation; Netherlands Ministry of Foreign Affairs; Universal Access to Female Condoms; USAID; The William and Flora Hewlett Foundation; individual contributors.

Strategies and tools to build healthy communities



VACCINES



DRUGS



DIAGNOSTICS



DEVICES



SYSTEM AND
SERVICE
INNOVATIONS

SYSTEM AND SERVICE INNOVATIONS

Health solutions can't deliver themselves. PATH collaborates with country partners using an array of innovations to strengthen health systems, encourage healthier behaviors, and increase access to affordable solutions.

A data-driven strategy to fight HIV/AIDS

powered by real-time information in the Democratic Republic of the Congo




SYSTEM AND SERVICE
INNOVATIONS

Our strategy for helping the Democratic Republic of the Congo (DRC) combat the HIV epidemic gives communities tools to protect themselves, care for those affected by HIV/AIDS, and build up the country's health system. The PATH-led ProVIC project has helped nearly 1.6 million people get HIV prevention information and 556,000 people receive HIV counseling and testing since 2009.

How do we know it's working? In 2013, PATH and our partners launched a cloud-based monitoring and evaluation database that allows ProVIC's staff to analyze and share data across five HIV "hotspots." For example, the data showed that many mothers in a program to prevent mother-to-child HIV transmission were not following up with treatment. In response, we launched a mother-to-mother mentoring program that more than doubled the number of women on treatment.

In 2013, PATH reached more than 325,000 people in the DRC with HIV prevention, care, and treatment services.



IMPACT

4,100+ health workers trained since 2009 to mobilize communities and reach the most vulnerable.

KEY PARTNERS: Chemonics International; Elizabeth Glaser Pediatric AIDS Foundation; International HIV/AIDS Alliance; nearly 100 local partners.

KEY FUNDER: US President's Emergency Plan for AIDS Relief through USAID.

A malaria parasite on the run

through a bold new strategy to eliminate this disease, country by country, once and for all



SYSTEM AND SERVICE
INNOVATIONS

You can see the future of malaria in Senegal's Richard Toll district. Since 2011, PATH has teamed up with employers, pharmacies, government agencies, and others to create zero-malaria-transmission zones by piloting innovative uses of drugs and diagnostics and improving the timeliness and quality of data reporting. In 2013, we expanded the approach to three new districts. Working with a network of partners across Senegal, we have contributed to a 62% drop in malaria deaths since 2006.

Now we are launching an ambitious new malaria agenda, joining forces with countries across Africa to scale up what's working while generating new approaches and commitments toward our ultimate goal: a malaria-free world.



Speak Up Africa

Teams of health workers in Senegal visit households where malaria is reported, testing and treating family members and neighbors to stop disease transmission.

IMPACT

A 51% drop in global malaria deaths in young children since 2000 through investments in proven interventions.

KEY PARTNERS: Governments of Ethiopia, Senegal, and Zambia; Roll Back Malaria Partnership.

KEY FUNDERS: Bill & Melinda Gates Foundation; individual contributors.

Solutions for Kenya's toughest health challenges

that engage communities and improve care at every level of the health system



SYSTEM AND SERVICE
INNOVATIONS

Through the PATH-led APHIA^{plus} Western Kenya project, East Africa's largest integrated health project, we are reaching into villages across western Kenya with proven strategies to tackle this region's greatest health threats, giving communities the tools to improve their health.

We established a new community-based motorcycle ambulance service that ensures pregnant women get to health clinics for deliveries. We trained some 5,600 community health workers to provide door-to-door health education and support. And we created a comprehensive malaria strategy that brings every available tool to the fight in one of Africa's highest transmission areas.

In all, we reached more than 3.7 million Kenyans in 2013 with integrated services for HIV/AIDS, malaria, maternal and child health, and tuberculosis.



PATH/Cabe Bienzycki

Motorcycle ambulances help pregnant women in remote communities reach skilled care in time to give birth.

IMPACT

A 25% increase in the number of pregnant women seeking skilled deliveries in health facilities supported by PATH in 2013.

KEY PARTNERS: Elizabeth Glaser Pediatric AIDS Foundation; Government of Kenya; Jhpiego; World Vision.

KEY FUNDER: USAID.

In 2013, PATH achieved top marks for financial stewardship.

TEN YEARS AT FOUR STARS



Charity Navigator,
America's largest
independent

evaluator of nonprofits, has
once again awarded PATH
its highest overall rating of
four stars.

This is PATH's tenth
consecutive year at four stars,
a designation that recognizes
our ability to efficiently
manage and grow our finances,
as well as our organizational
accountability and
transparency. Just 1 percent of
the more than 7,000 charities
rated by Charity Navigator can
say the same.

2013 FINANCIAL SUMMARY

REVENUE (in thousands)	
Foundations	\$149,791
US government	104,549
Other governments, nongovernmental organizations (NGOs), multilaterals	45,218
Investments	7,323
Individuals/other	6,283
Corporations	1,964
TOTAL REVENUE	\$315,128

EXPENSES (in thousands)	
Program services	
PROGRAMS:	
Product development	\$57,935
International development	49,346
Public health impact	29,090
Cross-program initiatives	5,522
Subtotal programs	141,893
Program subawards	124,793
Subtotal program services	\$266,686
Support services	
Management and general	\$41,957
Fundraising	2,939
Bid and proposal	2,433
Subtotal support services	\$47,329
TOTAL EXPENSES	\$314,015


ASSETS (in thousands)	
Cash and cash equivalents	\$88,011
Invested grant funds	240,323
Contributions and awards receivable	337,191
Other	23,974
TOTAL ASSETS	\$689,499

LIABILITIES AND NET ASSETS (in thousands)	
Total liabilities	\$58,028
Net assets	
Temporarily restricted	\$605,699
Unrestricted	22,394
Permanently restricted	3,378
Total net assets	\$631,471
TOTAL LIABILITIES AND NET ASSETS	\$689,499


Figures are presented in US dollars.

Notes: The above financial summary is based on PATH's audited financial statements, which are audited by the firm Clark Nuber P.S. Full copies are available on our website at www.path.org.


PATH is an international, nonprofit, nongovernmental organization. Our mission is to improve the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors. Contributions to PATH are tax-exempt under US IRS code 501(c)(3).



- 47.6% Foundations
- 33.2% US government
- 14.3% Other governments, NGOs, multilaterals
- 2.3% Investments
- 2.0% Individuals/other
- 0.6% Corporations



- 49.7% Product development
- 28.8% International development
- 19.1% Public health impact
- 2.4% Cross-program initiatives



- 84.9% Program services
- 13.4% Management and general
- 0.9% Fundraising
- 0.8% Bid and proposal

And we harnessed the talents of leaders driven to connect innovation and impact.

“Innovation is more than the act of invention. Truly transformative innovation means accelerating our best ideas through the development pipeline to get lifesaving solutions into the hands of the people who need them. Our talented leaders combine proven expertise across a range of disciplines, deep operational experience, and a passion for propelling innovation forward.”

—Steve Davis

President and CEO, PATH

BOARD OF DIRECTORS

Jo Addy, MBA, MPA

United States

Founder and Managing Director,
Alsweb Business Advantage
Woodside, CA USA

Dean Allen VICE CHAIR & TREASURER

United States

CEO, McKinstry
Seattle, WA USA

Kofi Amegashie, MSc

Ghana

Managing Executive, Africa,
Adcock Ingram
Johannesburg, South Africa

Phyllis Campbell, MBA

United States

Chairman, Pacific Northwest,
JPMorgan Chase & Co.
Seattle, WA USA

Alex Chika Ezeh, PhD, MSc

Nigeria

Executive Director,
African Population and Health
Research Center
Nairobi, Kenya

George Gotsadze, MD, PhD CHAIR

Republic of Georgia

Director, Curatio International Foundation
Tbilisi, Georgia

Eivor Halkjaer SECRETARY

Sweden

Former Swedish Ambassador and
Former Senior Advisor to the Director
General, Swedish International Development
Cooperation Agency
Stockholm, Sweden

David King, JD

United States

Chairman and CEO, LabCorp
Burlington, NC USA

Vincent McGee

United States

Former Senior Advisor,
The Atlantic Philanthropies
New York, NY USA

Felix Olale, MD, PhD

Kenya

Executive Chairman, Excelsior Group
New York, NY, USA, and Nairobi, Kenya

Kevin Reilly, MBA

United States

Former President,
Wyeth Vaccines and Nutrition
Rosemont, PA USA

Rajendra Vattikuti, MS

United States

Founder and Former President and CEO,
Covansys, and
Founder, Vattikuti Foundation
Southfield, MI USA

EXECUTIVE TEAM

Ayo Ajayi, MD, MPH

Vice President, International Development

Amie Batson, MBA

Chief Strategy Officer

Steve Davis, MA, JD

President and CEO

David C. Kaslow, MD

Vice President, Product Development

Michael Kollins

Chief Operating Officer

Daniel Laster, JD

General Counsel

Roger Nyhus

Vice President, Global Engagement and
Communications (interim)

Kathryn O'Driscoll

Chief Human Resources Officer

Olivia Polius

Chief Financial Officer

Jacqueline Sherris, PhD

Vice President, Public Health Impact

PROGRAM LEADERS

INTERNATIONAL DEVELOPMENT

Mona Byrkit, MPH

Mekong region

Carlos C. (Kent) Campbell, MD, MPH

Malaria Control Program

Dwan Dixon, MPH, MA

Ethiopia

Kateryna (Katya) Gamazina, MD

Ukraine

Philippe Guinot, MBA

Senegal

Win May Htway, MD, MPH

Myanmar

Mohammed Makame, MD, MPH

Tanzania

Nanthalile Mugala, MD, MMed

Zambia

Emmanuel Mugisha, PhD, MPH

Uganda

Kevin Osborne, BA (Hons) HDE

South Africa

Mary Prum

Cambodia

Rikka Trangsrud, MA

Kenya

Tarun Vij, MBA

India

PRODUCT DEVELOPMENT

Ashley Birkett, PhD

Malaria Vaccine Initiative

John Boslego, MD

Vaccine Development

Anurag Mairal, PhD, MBA

Technology Solutions

Kathleen Neuzil, MD, MPH

Vaccine Access and Delivery

Ponni Subbiah, MD, MPH

Drug Development

Jiankang (Jack) Zhang, MS, MBA

China

PUBLIC HEALTH IMPACT

Grant Colfax, MD

HIV/AIDS and Tuberculosis

Jane Hutchings, MPH

Reproductive Health

Dai Hozumi, MD

Maternal and Child Health and Nutrition
(interim)

PATH OFFICE LOCATIONS

Bangladesh | Dhaka

Belgium | Brussels

Cambodia | Phnom Penh

China | Beijing

Democratic Republic of the Congo | Bunia,
Kinshasa, Kisangani, Lubumbashi

Ethiopia | Addis Ababa

France | Ferney-Voltaire

Ghana | Accra, Kpaguri, Kumasi

India | Lucknow, Mumbai, New Delhi

Kenya | Bungoma, Busia, Homa Bay,
Kakamega, Kisii, Kisumu, Migori, Nairobi

Mozambique | Maputo

Myanmar | Yangon

Peru | Lima

Senegal | Dakar

South Africa | Empangeni, Johannesburg,
Kuruman, Sedibeng, Witbank

Switzerland | Geneva

Tanzania | Arusha, Dar es Salaam

Uganda | Kampala

Ukraine | Kyiv

United States | Seattle, South San Francisco,
Washington, DC

Vietnam | Hanoi

Zambia | Lusaka, Ndola

Your support fuels
transformative
innovation that touches
millions around the
world. Thank you.

Our supporters are essential partners in our work to bring innovation to life. In 2013, more than 2,500 individual donors, foundations, corporations, and institutions invested in that work.

Flexible funding from our individual contributors plays a catalytic role in accelerating innovation, helping to advance many of the milestones highlighted in this report. For a complete list of our supporters, please visit www.path.org/annual-report/2013/.

Thank you for your commitment to improving health and saving lives around the world!



Explore our full annual report online:

www.path.org/annual-report/2013/

DISCOVER

www.path.org

FOLLOW

www.facebook.com/PATHglobalhealth

www.twitter.com/PATHtweets

GIVE

www.path.org/donate/



PO Box 900922
Seattle, WA 98109 USA
206-285-3500